Effects of remimazolam on gastrointestinal motility and gastrointestinal hormones in patients undergoing gastrointestinal endoscopy

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200057676

Enrollment

Unknown

Registered

2022-03-15

Start date

2022-03-16

Completion date

Unknown

Last updated

2023-11-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

R:Intravenous injection of 0.2mg of butorphanol and 0.2 ~ 0.25mg/kg of remimazolam

P:Intravenous injection of 0.2mg of butorphanol and 1.5~2mg/kg of propofol

C:NA

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Patients undergoing painless gastroscopy and enteroscopy under single anesthesia; 2. ASA Class I-II; 3. Age: 18-65, regardless of gender; 4. Body mass index (BMI): 28kg/m2 = BMI = 18kg/m2.

Exclusion criteria

Exclusion criteria: 1. Poor compliance and failure to cooperate; 2. Pregnant or lactating women; 3. Endoscopic surgery (polypectomy, ESD, etc.); 4. Recently taken drugs that affect gastrointestinal motility (motiline, mosapride, M1 receptor agonists/inhibitors, etc.) or sedatives; 5. Gastrointestinal endoscopy takes too long (= 20min); 6. Allergies to opioids, benzodiazepines or propofol drugs.

Design outcomes

Primary

Measure	Time frame
Sectional area of gastric antrum;Percentage of coordinated contraction of antrum, pylorus and duodenum;Peristaltic cycle of stomach;Number of sigmoid movements;ghrelin;motilin;gastrin;cholecystokinin;somatostatin;	—

Countries

China

Contacts

Public ContactGaofeng Zhang

Affiliated Qingdao Municipal Hospital of Qingdao University

exgalaxy@163.com+86 18661607191

Outcome results